Skip to main content

Advertisement

Table 1 Characteristics of cases and controls

From: DNA methylation in repeat negative prostate biopsies as a marker of missed prostate cancer

Characteristic Cases (n = 111) Controls (n = 129)
Age at first biopsy, median years (IQR) (missing: 0) 66.2 (61.9–70.7) 65.6 (59.5–69.2)
Calendar year at first biopsy, median (IQR) (missing: 0) 2002 (98–04) 2003 (01–05)
Time interval between the first and second biopsy, median months (IQR) (missing: 0) 21.9 (11.9–37.1) 22.5 (12.7–41.5)
Time interval between the first biopsy and the index sampling, median months (IQR) (missing: 0) 44.5 (27.2–74.3) 45.9 (27.1–73.5)
Number of patients per ward (%) (missing: 0)
 Ward I 86 (77.5) 100 (77.5)
 Ward II 25 (22.5) 29 (22.5)
GSTP1 methylation %, median (IQR)
 First biopsy (missing: 8 cases, 14 controls) 3.25 (1.75–5.50) 2.75 (1.37–4.25)
 Second biopsy (missing: 7 cases, 8 controls) 3.25 (2.00–6.00) 2.75 (1.75–3.75)
 Difference between the second and the first biopsy (missing: 14 cases, 20 controls) 0.00 (− 2.25–2.25) 0.00 (− 1.00–1.25)
PITX2 methylation %, median (IQR)
 First biopsy (missing: 18 cases, 23 controls) 8.75 (4.75–11.75) 8.25 (5.12–11.19)
 Second biopsy (missing: 17 cases, 14 controls) 8.25 (5.50–12.19) 9.00 (5.75–12.87)
 Difference between the second and the first biopsy (missing: 30 cases, 30 controls) − 1.00 (−6.00–5.25) 0.00 (− 3.62–4.25)
APC methylation %, median (IQR)
 First biopsy (missing: 15 cases, 21 controls) 1.33 (1.00–3.08) 1.33 (1.33,3.33)
 Second biopsy (missing: 16 cases, 17 controls) 1.33 (1.00–3.92) 1.33 (1.00–3.67)
 Difference between the second and the first biopsy (missing: 29 cases, 33 controls) 0.00 (−1.33–1.83) 0.17 (− 0.33–1.42)
C1orf114 methylation %, median (IQR)
 First biopsy (missing: 18 cases, 19 controls) 4.00 (2.00–8.50) 2.50 (1.50–5.50)
 Second biopsy (missing: 12 cases, 9 controls) 5.00 (1.50–9.25) 4.50 (1.50–7.12)
 Difference between the second and the first biopsy (missing: 28 cases, 23 controls) 0.00 (− 3.25–4.50) 0.50 (− 2.00–4.50)
GABRE methylation %, median (IQR)
 First biopsy (missing: 27 cases, 38 controls) 2.70 (1.00–6.30) 2.00 (1.00–4.90)
 Second biopsy (missing: 28 cases, 25 controls) 2.60 (1.00–5.50) 1.90 (1.00–5.20)
 Difference between the second and the first biopsy (missing: 44 cases, 51 controls) − 0.20 (−1.90–2.40) 0.00 (− 2.00–1.80)
LINE-1 methylation %, median (IQR)
 First biopsy (missing: 5 cases, 7 controls) 69.7 (66.0–74.0) 69.3 (66.3–72.6)
 Second biopsy (missing: 3 cases, 3 controls) 69.3 (66.2–72.1) 69.0 (66.1–73.0)
 Difference between the second and the first biopsy (missing: 24 cases, 30 controls) 0.00 (− 3.33–4.00) 0.17 (− 4.00–4.08)
Gleason score (missing: 2 cases)
 6 28 (25.7)
 3 + 4 53 (48.6)
 4 + 3 13 (11.9)
 8+ 15 (13.8)
PSA at the second biopsy, median (IQR) (missing: 22 cases, 19 controls) 9.15 (6.02–13.00) 8.00 (6.00–10.16)
  1. IQR interquartile range, PSA prostatic-specific antigen